-

01:08:54 AM

CRSP Stock News

CRSP - CRISPR Therapeutics AG

05/16/22 4:01 PM

Nasdaq : CRSP

management

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief

RHEA-AI

positive

05/12/22 10:33 AM

Nasdaq : CRSP

clinical trial

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the

RHEA-AI

neutral

05/09/22 4:01 PM

Nasdaq : CRSP

earnings

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110™, targeting

RHEA-AI

neutral

05/04/22 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

04/12/22 4:01 PM

Nasdaq : CRSP

management

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board of

RHEA-AI

neutral

04/07/22 4:01 PM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

03/08/22 4:35 PM

Nasdaq : CRSP

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an e-poster at the American Association for

RHEA-AI

neutral

02/28/22 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

02/15/22 4:01 PM

Nasdaq : CRSP

earnings

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110™, targeting CD19+ B-cell malignancies; additional data

RHEA-AI

positive

02/09/22 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

1 2 3 4 5 6 Next

CRSP Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitecrisprtx.com
CeoSamarth Kulkarni
Security nameCRISPR Therapeutics AG
Issue typecs
SectorManufacturing
Sic code2836
Employees410
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressBaarerstrasse 14
StateZug
CityZug
Zip6300
CountrySwitzerland
Phone41415613277

About CRISPR Therapeutics AG

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.